Biology Oriented Investigation of Treatment Strategies for Acute Myeloid Leukemia (AML): The AMLCG Approach

摘要: The outcome in patients with AML appears influenced by some therapeutic variables such as different intensity chemotherapy, growth factor priming, autologous or allogeneic transplantation. Even more than treatment the is determined genetic and functional features related to individual disease biology. Open questions are how far these prognostic factors apply options whether prognosis specific subgroups can be improved treatment. We here present a new study strategy using upfront randomization for major alternatives, stratified de novo versus secondary MDS, their biologic thus allowing unbiased analyses of subgroup-specific effects treatments.